Posted by: Process Matters Blogger in: ● December 20, 2010
Last September, as you probably remember, Allergan reached a $600M settlement regarding its off label promotion of BOTOX—which sparked some interesting dialogue about leveraging business process management software to solve new compliance requirements within the pharmaceutical industry. Starting January 2012, U.S. federal government has required that all pharmaceutical companies document, track and report a wide [...]
Posted by: Process Matters Blogger in: ● October 5, 2010
Metastorm customers are continuing to receive tons of recognition for their business process improvement initiatives! Last week Metastorm announced that the City of Richmond, VA has received multiple awards for its CommonCents initiative built on Metastorm BPM® software platform. Today, Metastorm announced that our valued customer AmerisourceBergen has been named runner-up in the 2010 Business [...]
Posted by: Ethan Smith in: ● September 8, 2010
Among the litany of headlines recently blasting pharmaceutical, biotech and medical device companies, Allergan – the makers of Botox – has been the latest scapegoat. The past week’s news has been full of stories relating to Allergan’s agreement to settle “off label promotion” charges to the tune of $600M. While the specifics of pleas and [...]
Posted by: Process Matters Blogger in: ● August 4, 2010
Pharmaceutical companies have found ease and success in deploying Metastorm Enterprise software to model, improve and optimize their processes and systems. In the newest season of the Metastorm Customers Speak Out video testimonial series, we take a deeper look into the strategic advantages Metastorm software offers Allergan, a global pharmaceutical company. In this video interview, [...]
Posted by: Tom Holmberg in: ● May 3, 2010
“It was the best of processes; it was the worst of processes…” Charles Dickenson’s A Tale of Two Cities describes the economic disconnect between the lavish lifestyles of the French Monarchy and the marginalized citizens of France. This same drama plays out in organizations where regional departments insist on maintaining their own processes in [...]
Posted by: Ethan Smith in: ● April 27, 2010
In today’s Life Sciences world everything is becoming increasingly more difficult – all of the “easy” drugs have been discovered, the human genome has been mapped and parts even patented (albeit with much dispute), the blockbuster model has crumbled, cost pressures are intensifying and regulatory scrutiny is at an all time high. The cries for [...]
